ScientiaCME The gMG care continuum: timely recognition, steroid-sparing strategy, and targeted therapy integration in generalized myasthenia gravis
In this online, self-learning activity:
Generalized myasthenia gravis (gMG) is an autoimmune neuromuscular junction disorder marked by fluctuating, fatigable weakness that can involve ocular, bulbar, limb, and respiratory muscles. In a U.S. claims-based analysis, diagnosed prevalence in 2021 was 37.0 per 100,000 and incidence was 3.1 per 100,000, underscoring a clinically meaningful population at risk for disability and episodic deterioration. Reviews describe persistent symptom burden and functional consequences that extend beyond clinic-based strength testing. Real-world observational data link higher disease severity to greater impairment in activities of daily living, including reduced independence with self-care and mobility. International consensus guidance recommends stepwise management with early steroid-sparing intent and timely adjustment when treatment targets are not met. Higher severity is also associated with worse work productivity and activity impairment, amplifying socioeconomic burden.
Cost: Free
View Offer chevron_rightDetails
In this online, self-learning activity:
Generalized myasthenia gravis (gMG) is an autoimmune neuromuscular junction disorder marked by fluctuating, fatigable weakness that can involve ocular, bulbar, limb, and respiratory muscles. In a U.S. claims-based analysis, diagnosed prevalence in 2021 was 37.0 per 100,000 and incidence was 3.1 per 100,000, underscoring a clinically meaningful population at risk for disability and episodic deterioration. Reviews describe persistent symptom burden and functional consequences that extend beyond clinic-based strength testing. Real-world observational data link higher disease severity to greater impairment in activities of daily living, including reduced independence with self-care and mobility. International consensus guidance recommends stepwise management with early steroid-sparing intent and timely adjustment when treatment targets are not met. Higher severity is also associated with worse work productivity and activity impairment, amplifying socioeconomic burden.
Learning Objectives
By the end of the session the participant will be able to:
- Describe gMG epidemiology, immunopathology, and key clinical phenotypes including bulbar and respiratory involvement
- Recall tools to identify degree of disease control
- Select and time conventional therapies and rescue options to minimize steroid burden and risk and integrate targeted therapies into individualized treatment plans
Target Audience
The following HCPs: neurologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in neurology; and any other healthcare professionals with an interest in or who clinically encounter patients with gMG.
Additional credit info
ACCME Activity #203757884
ScientiaCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-26-029-H01-P. This is an Application (A) type activity.

Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner’s responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.